Research programme: anti-HER2 antibody gene therapy - Voyager Therapeutics
Latest Information Update: 09 Aug 2023
At a glance
- Originator Voyager Therapeutics
- Class Antineoplastics; Gene therapies; Immunotherapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Brain metastases; Breast cancer